EUCTR2004-002093-30-ES进行中（未招募）1 期
Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon a-2a (PEG-IFN) or Roferon-A in prior clinical studies.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Patients must have completed protocol NO15753, NO15764, NO16006 or NO16007 and responded to treatment at the end of the trial as defined in the parent protocol.
- •- CML patients must have a confirmed cytogenetic complete response within 2 months of entering the extension study. MM and RCC patients must have tumour assessments verifying stable or better response within 2 months of entering the extension study.
- •- Provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Pregnant or lactating women.
- •- Fertile men or women of childbearing potential unless
- •(1) surgically sterile or
- •(2) using adequate measures of contraception such as oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly.
研究者
相似试验
已完成
2 期
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical StudiesMalignant MelanomaRenal Cell CarcinomaChronic Myelogenous LeukemiaNCT02829775Hoffmann-La Roche9
进行中（未招募）
1 期
Protocolo de extensión para pacientes con esclerosis múltiple que participaron en los estudios de alemtuzumab patrocinados por Genzyme./An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab.Esclerosis Multiple de Recaida-Remision/Relapsing Remitting Multiple SclerosisMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-010788-18-ESGenzyme Corporation1,500
已完成
3 期
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab10012303MSMultiple SclerosisNL-OMON41482Genzyme Corporation5
进行中（未招募）
1 期
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabRelapsing Remitting Multiple SclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2009-010788-18-BEGenzyme Corporation1,500
进行中（未招募）
不适用
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of AlemtuzumabEUCTR2009-010788-18-DKGenzyme Corporation1,500